GILD vs PFE
Gilead Sciences and Pfizer, both Healthcare
Gilead Sciences is the larger company at $154B against $144B. Over the past year GILD returned +36% against +23% for PFE. The RyuScore puts PFE ahead, 61 against 44 out of 100.
| Figure | GILD | PFE |
|---|---|---|
| Last close | $151 | $28.27 |
| Market cap | $154B | $144B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 37.2 |
| Dividend yield | 2.1% | 6.1% |
| 1-year return | +36% | +23% |
| 5-year return | +155% | -19% |
| RyuScoresector-relative, 1–10 | 44/100 | 61/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Gilead Sciences
Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.
Pfizer
Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 16% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.